Ursotab is indicated for the treatment of-
Ursotab is used to reduce the cholesterol saturation of bile and to promote the dissolution of gallstones. The cholesterol saturation of bile is reduced by Ursotab, allowing gradual solubilization of cholesterol gallstones. Cholesterol secretion into bile is reduced, and the bile acid secretion rate is increased during Ursotab treatment without a reduction in phospholipids.
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Ursodeoxycholic Acid is a naturally occurring bile acid used to treat different hepatobiliary disorders. The activity of Ursodeoxycholic Acid is achieved through a decrease in secretion of cholesterol in bile. Ursodeoxycholic Acid achieves this through a few mechanisms: it reduces cholesterol absorption, suppresses liver cholesterol synthesis and it does not inhibit bile acid synthesis.
Therefore, alters bile composition from saturated to unsaturated. Ursodeoxycholic Acid also promotes the formation of liquid cholesterol crystal complexes, which enhance removal of the cholesterol from the gallbladder into the intestine to be expelled. Ursodeoxycholic Acid improves cholestatic liver diseases by-
Ursodeoxycholic Acid is completely absorbed in the upper intestine. Time to peak serum concentration varies from 30 to 150 minutes. The rate of absorption ranges from 60-80%. After absorption, Ursodeoxycholic Acid enters the portal vein and undergoes extraction from portal blood by the liver, where it is conjugated with an amino acid, which may be either glycine or taurine, and then secreted into the hepatic bile ducts. Small quantities of Ursodeoxycholic Acid appear in the circulation, and very small amounts are excreted into urine. The biologic half-life of Ursodeoxycholic Acid ranges from 3.5-5.8 days.
Ursotab should not be used with drugs, such as oestrogenic hormones, that increase bile cholesterol. Concomitant administration with bile-acid-binding drugs, including antacids, charcoal, and cholestyramine, should be avoided, since this may reduce the effectiveness of therapy with Ursotab.
Pregnancy category B. No evidence of harm has been reported in pregnancy. It has been effectively used for the treatment of cholestasis of pregnancy during the last trimester without any side effects. No problems have been documented in humans regarding breastfeeding.
Store below 25° C. Protected from light and moisture. Keep the medicine out of the reach of children.
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.